Global Aliskiren Market Size By Type (150 mg Tablet and 300 mg Tablet), By Application (Hospital and Drug Store), By Geographic Scope And Forecast

Aliskiren Market Size And Forecast

Aliskiren Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028

What's fueling the Aliskiren Market's growth? Well, it's largely due to how well aliskiren works at managing hypertension. Plus, it plays nice with other blood pressure meds, helping more folks get their blood pressure under control.

We're also seeing a boost from more government programs and people being more aware of their health. However, it's not all smooth sailing. The pricey ingredients and production challenges could slow things down a bit.

Want the full scoop? The Global Aliskiren Market report gives you a complete look – digging into the key parts, trends, what's helping and hurting, who's competing, and everything else that matters in the market.

Global Aliskiren Market Definition

So, Aliskiren (you might know it as Tekturna or Rasilez) is the pioneer of a new kind of medicinedirect renin inhibitors. Doctors prescribe it mainly for essential (or primary) hypertension – that's just high blood pressure. Basically, these renin inhibitors stop renin, an enzyme, from kicking off a whole chain of events that controls your blood pressure. This action helps your blood vessels loosen up and get wider, making it simpler for blood to flow through. Aliskiren, being the first of its kind that you can take by mouth, used to be a go-to for hypertension. Now, renin comes from special kidney cells that notice changes in blood flow and pressure thanks to some stretch receptors. Believe it or not, the whole point of aliskiren is supposed to be to increase blood pressure in the long run, so blood flow to the kidneys goes back to normal. But Renin-inhibitors like Aliskiren block renin which causes blood vessels to widen!

Aliskiren is an antagonist to renin. Renin, the first enzyme in the renin-angiotensin-aldosterone system, plays a role in blood pressure control. It converts angiotensinogen to angiotensin I, which is then converted to angiotensin II by an angiotensin-converting enzyme. Angiotensin II is a potent vasoconstrictor that causes the blood pressure to rise. Angiotensin II also stimulates the production of aldosterone from the adrenal cortex, which causes the tubules of the kidneys to increase reabsorption of sodium, with water following, thereby increasing plasma volume, and thus blood pressure. Aliskiren is also available as a combination therapy with hydrochlorothiazide.

Global Aliskiren Market Overview

The role of aliskiren in the treatment of hypertensive diabetic patients is the major driver propelling the market growth. Standard treatments available today for treating hypertension are diuretics, angiotensin-converting enzyme inhibitors (ACEs), calcium channel blockers, a-blockers, vasodilators, and centrally acting drugs. Key factors expected to drive the growth of the global Aliskiren Market is increasing effectiveness in controlling hypertension, aliskiren can be combined with all classes of current antihypertensive drugs, increasing the number of patients achieving blood pressure control.

Moreover, an increase in government initiatives and a rise in health awareness are the factors expected to augment the global market. An increase in demand for personalized medicines, and better diagnostic facilities are likely to propel the global Aliskiren market. However, poor absorption from the gastrointestinal tract, less bioavailability, short half-life, and low potency hindered the development of these compounds. Also, the high cost of the components of the aliskiren medicines and the production constrain the growth of the market.

Global Aliskiren MarketSegmentation Analysis

The Global Aliskiren Market is segmented based on Type, Application and Geography.

Aliskiren Market, By Type

• 150 mg Tablet
• 300 mg Tablet
• Other

Based on Type, the market is bifurcated into 150 mg Tablet, 300 mg Tablets, and Other.

Aliskiren Market, By Application

• Hospital
• Drug Store
• Other

Based on the Application, the market is bifurcated into Hospital, Drug stores, and Other.

Aliskiren Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Aliskiren Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The Aliskiren Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Aliskiren Market ecosystem results in the increasing adoption of these systems in North America.

Key Players

The “Global Aliskiren Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Noden Pharma, LGM Pharma, Cayman, Vitae-GSK, Daiichi Sankyo, Novartis, Merck-Frost, Mitsubishi-Tanabe, Takeda, and Cadila Healthcare.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

Partnerships, Collaborations and Agreements

• GlaxoSmithKline plc (GSK) and Alector announced a strategic global agreement in July 2021 to develop and commercialize two clinical-stage, possible first-in-class monoclonal antibodies (AL001 and AL101) targeted to boost progranulin (PGRN) levels. Alector’s world-class immuno-neurology expertise will be combined with GSK’s R&D focus on the immune system and human genetics, as well as its proven late-stage drug development capabilities and global footprint.

Mergers and Acquisitions

• In July 2020, private equity firm Stanley Capital announced that it had reached a definitive agreement with PDL BioPharma, Inc. to acquire Noden Pharma DAC, a leading specialized pharmaceutical company in the cardiovascular domain.

• In January 2020, Novartis AG announced that it had completed the acquisition of The Medicines Company by completing a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation, with and into the Company, with the Company surviving the merger, without a vote of the Company’s stockholders, under Section 251(h) of the Delaware General Corporation Law.

• In July 2020, Nexgen Pharma, Inc.’s formulation development and drug product contract manufacturing company has been bought by LGM Pharma. The merger combines LGM Pharma’s global experience in API procurement, distribution, and supply chain management with Nexgen Pharma’s comprehensive drug product contract development and manufacturing (CDMO) capabilities.

Product Launches and Product Expansions

• LGM Pharma announced the launch of its new Analytical Services offering in July 2021, which provides analytical testing and stability services to pharmaceutical inventors and manufacturers, as well as compounding pharmacies. The company, which already provides analytical services as part of its integrated contract development and manufacturing (CDMO) activities, is now offering its analytical services knowledge and facilities to pharmaceutical sector clients as an independent contract service.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We'll dig into the market with both qualitative and quantitative analysis, breaking it down by segments using everything from economic trends to other important factors. You'll get hard data – market values in USD Billion – for each segment and sub-segment. We'll pinpoint which region and segment is predicted to grow the fastest and eventually lead the pack. Plus, we'll analyze how different regions are consuming the product or service, and what's influencing the market in each area. Think of it like a geographical breakdown to see what is going on everywhere. The report will also cover the competitive scene, ranking major players and highlighting recent launches, partnerships, expansions, and acquisitions from the last five years. You will see detailed company profiles with overviews, insights, product comparisons, and SWOT analyses for all the big names. You'll get a clear picture of the industry's present and future, looking at recent happenings like growth opportunities, driving forces, and challenges across both new and established regions. It even includes a detailed look at the market from different angles, using Porter's Five Forces. We'll provide market insights through the value chain, paint a picture of the market's dynamics, and highlight growth opportunities in the years ahead. And to top it off, you'll get six months of analyst support after your purchase.

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.